- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02253693
Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry
Descriptive Pilot Study of Monitoring of Physical Activity in Adult Patients With Haemophilia A Arthropathy by Means of Accelerometry, Image Tests and Physical Condition Parameters. Benefits Associated With That Monitoring"
Research Question: Does an specific and pre-defined physical exercise prescribed by a specialist provide any benefit on haemophilic arthropathy, the quality of life or the physical condition of patients with haemophilia A and haemophilic arthropathy? Does adherence to physical exercise improve when monitoring patients with an accelerometer? Do compliant patients find higher benefit on haemophilic arthropathy, quality of life or the physical condition than non-compliant patients?
Primary Endpoint: Assess in patients with haemophilia A and haemophilic arthropathy if a prescribed and specific physical exercise monitored by an accelerometer is producing any change in the following domains: progress of haemophilic arthropathy; health-related quality of life; physical condition.
Secondary Endpoints: Evaluate the adherence to physical exercise in patients with haemophilia A and haemophilic arthropathy by means of accelerometry, and asses if compliant patients achieve higher improvement in these 3 domains than non-complaint patients.
Study Overview
Status
Conditions
Detailed Description
Specific details of Treatment/Intervention:
Physical exercises that are part of the specific medical program prescribed for each patient. The exercise program for each patient will depend of the haemophilic arthropathy, the level of physical condition and the preferences of the patient.
Monitoring of physical activity will be made by means of accelerometers. Its use does not alter the daily activities and does not require any change of the patients' individual habits. The assessment of the patients' cardiovascular condition will be made using pulse monitors. Normal examinations in clinical practice will be revised as well as those specific to each patient reference health centre, muscle strength and joint use testing which will be validated with force measurement devices. Assess by means of an ultrasound system the baseline situation of the joints used for daily activities for injury control. Determine the likelihood of fracture and assess the bone quality by means of densitometry. Thermal cameras will allow to analyse the characteristics of Joint inflammation. It may be suitable for bleeding evolution control. Measurements given by densitometers will allows to determine the state of bones of the participants in the study (osteoporosis measurement). Number of bleeding events/hemarthrosis during the period of study. Determine the activity of hemarthros/synovitis using thermal images.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46010
- University of Valencia
-
Valencia, Spain, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patients over 18
- Patients diagnosed with haemophilia A and under prophylaxis treatment with the same FVIII for 2 years prior to the inclusion in the study.
- Patients with haemophilic arthropathy in, at least, one of the four load-bearing joints (knees and ankles), according to clinical and/or radiographic criteria (at least 3 in the Gilbert scale and /or at least 3 in the Pettersson scale) and/or Chronic synovitis evidenced by ultrasound.
- Patients with signed informed consent.
Exclusion Criteria:
- Patients who have developed an inhibitor antibody (≥5 Bethesda units), at the moment of the inclusion in the study.
- Development of inhibitors
- Modification, during follow-up, of FVIII with which the patient started the study.
- The patient decides to withdraw voluntarily from the study.
- Major orthopaedic surgery
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Patients with haemophilia
Adult patients with haemophilia A presenting joint disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the physiotherapy treatment compliance. Parameters: Intensity, duration, type of exercise and % of compliance.
Time Frame: After 6, 12, 18 and 24 months.
|
Level of treatment compliance assessed by the intensity (counts/min), duration (m) and type of exercise measured with triaxial accelerometer.
|
After 6, 12, 18 and 24 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age (years).
Time Frame: In month 0, and month 24.
|
Age of patient.
|
In month 0, and month 24.
|
Weight (Kg).
Time Frame: In month 0, and month 24.
|
Weight of patient.
|
In month 0, and month 24.
|
Biochemistry and haemogram tests. The parameters to be reported are: Leukocyte (mil/mm3), Lymphocyte (mil/mm3), Haemoglobin (g/dl), Glucose (mg/dl), Total, HDL and LDL cholesterol (mg/dl), Triglyceride (mg/dl) and Creatine phosphokinase (CPK) (UI/L).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
In Baseline and after 6, 12, 18 and 24 months.
|
|
Prophylactic treatment with Factor VIII. Parameters: Trough levels of FVIII in blood (% FVIII) and type of FVIII and dose (UI/ week).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
In Baseline and after 6, 12, 18 and 24 months.
|
|
Body composition of patient. Parameters: BMI (Kg/m^2) and % of body fat.
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
In Baseline and after 6, 12, 18 and 24 months.
|
|
Cardiovascular condition. Parameters: Beats/minute and distance covered (metres).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Beats/minute measured with a pulse monitor and distance covered in Six-minute walk test (6MWT).
|
In Baseline and after 6, 12, 18 and 24 months.
|
Blood pressure (mmHg).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Measured with Cuff- stethoscope; Manometer; manual meter.
|
In Baseline and after 6, 12, 18 and 24 months.
|
Muscle strength in kilos (peak force and time to reach peak force).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Measured with Lafayette device.
|
In Baseline and after 6, 12, 18 and 24 months.
|
State of joints and injury control (HJHS 2.1. score).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Evaluated by ultrasound system.
|
In Baseline and after 6, 12, 18 and 24 months.
|
Joint inflammation. Parameters: Thermal imaging (ºC) and joint perimeter (cm).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Measured with thermal camera and tape measure.
|
In Baseline and after 6, 12, 18 and 24 months.
|
Bone density. Parameter: Bone Quality Index (BQI).
Time Frame: In Baseline and in month 24.
|
Densitometry.
|
In Baseline and in month 24.
|
Bleeding/ hemarthrosis. Parameter: Bleeding Rate (BR).
Time Frame: In Baseline and after 6, 12, 18 and 24 months.
|
Registered in patient's diary.
|
In Baseline and after 6, 12, 18 and 24 months.
|
Health-related quality of life. Parameters: General questionnaire (EQ-5D EuroQoL) and specific questionnaire (A36 Hemophilia QoL).
Time Frame: In Baseline and in 12 and 24 month.
|
In Baseline and in 12 and 24 month.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Felipe Querol-Fuentes, University of Valencia
Publications and helpful links
General Publications
- Rodríguez-Merchan EC, Goddard NJ, Lee CA, editors. Musculoskeletal Aspects of Haemophilia. Oxford: Blackwell Sciencie Ltd; 2000.
- Gonzalez LM, Peiro-Velert C, Devis-Devis J, Valencia-Peris A, Perez-Gimeno E, Perez-Alenda S, Querol F. Comparison of physical activity and sedentary behaviours between young haemophilia A patients and healthy adolescents. Haemophilia. 2011 Jul;17(4):676-82. doi: 10.1111/j.1365-2516.2010.02469.x. Epub 2011 Feb 7.
- Hendelman D, Miller K, Baggett C, Debold E, Freedson P. Validity of accelerometry for the assessment of moderate intensity physical activity in the field. Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S442-9. doi: 10.1097/00005768-200009001-00002.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H14-23641
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A, Congenital
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
University of British ColumbiaBiogenCompletedHemophilia A, Congenital | Hemophilia B, CongenitalCanada
-
CSL BehringCompletedCongenital Hemophilia AUnited States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
-
BayerCompletedHemophilia A, CongenitalSlovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
-
Grifols Therapeutics LLCGrifols Biologicals, LLCTerminatedHemophilia A, CongenitalUnited States, Spain, Italy, India, Canada, Russian Federation
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia